Different Effects on Protein Expression of CDR132L, an Antisense Inhibitor of miR-132, and Standard Therapies for Myocardial Infarction

Front Cardiovasc Med. 2022 May 13:9:887236. doi: 10.3389/fcvm.2022.887236. eCollection 2022.

Oriol Iborra-Egea^{1

2}, Alberto Aimo^{3

4}, Antoni Bayes-Genis^{1

2

5}

¹ ICREC (Heart Failure and Cardiac Regeneration) Research Programme, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Barcelona, Spain.
² Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
³ Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
⁴ Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
⁵ CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain.

No abstract available

Keywords: CDR132L; heart failure; models; myocardial infarction; therapy.